Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1 G93A amyotrophic lateral sclerosis (ALS) mice
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17448 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Laura Moreno-Martinez und 17 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Superoxide Dismutase-1, Tacrolimus Binding Protein 1A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agencia Estatal de Investigación, Ikerbasque, Basque Foundation for Science, Euskal Herriko Unibertsitatea.
Abstract (Originalsprache)
Background and Purpose Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with limited treatment options. ALS pathogenesis involves intricate processes within motor neurons, characterized by dysregulated Ca 2+ influx and buffering in early ALS‐affected motor neurones. This study proposes the modulation of ryanodine receptors (RyRs), key mediators of intracellular Ca 2+ , as a therapeutic target. Experimental Approach A novel class of novel FKBP12 ligands that show activity as cytosolic calcium modulators through stabilizing RyR channel activity, were tested in the superoxide dismutase 1 (SOD1) G93A mouse model of ALS. Different outcomes were used to assess treatment efficacy, including electrophysiology, histopathology, neuromuscular function and survival. Key Results Among the novel FKBP12 ligands, MP‐010 was chosen for its central nervous system availability and favourable in vitro pharmaco‐toxicological profile. Chronic administration of MP‐010 to SOD1 G93A mice produced preservation of motor nerve conduction, with the 61‐mg·kg −1 dose significantly delaying the onset of motor impairment. This was accompanied by improved motor coordination, increased innervated endplates and significant preservation of motor neurones in the spinal cord of treated mice. Notably, MP‐010 treatment significantly extended lifespan by an average of 10 days compared to vehicle. Conclusions and Implications FKBP12 ligands, particularly MP‐010, exhibit promising neuroprotective effects in ALS, highlighting their potential as novel therapeutic agents. Further investigations into the molecular mechanisms and clinical translatability of these compounds are needed for their application in ALS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
- LAGENBIO, Faculty of Veterinary, University of Zaragoza, Zaragoza, Spain.
- Aragón Health Research Institute (IIS Aragón), Biomedical Research Centre of Aragón (CIBA), Zaragoza, Spain.
- AgriFood Institute of Aragon-IA2 (UNIZAR-CITA), Zaragoza, Spain.
- Department of Cell Biology, Physiology and Immunology, Institute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, Spain.
- Group of Neurosciences, Departments of Pediatrics and Neuroscience, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), San Sebastian, Spain.
ORCID-Profile: Laura Moreno-Martinez, Núria Gaja-Capdevila, Laura Mosqueira-Martín, Mireia Herrando-Grabulosa, Laura Rodriguez-Gomez, Ana C Calvo, Maialen Sagartzazu-Aizpurua, Leticia Moreno-García, Jose Manuel Fuentes, Abraham Acevedo-Arozena, Jesús María Aizpurua, José Ignacio Miranda, Ainara Vallejo-Illarramendi, Xavier Navarro, Rosario Osta, Francisco Javier Gil-Bea
Förderung
- Agencia Estatal de Investigación
- Ikerbasque, Basque Foundation for Science
- Euskal Herriko Unibertsitatea
- CIBER-CALS
- Instituto de Salud Carlos III of Spain
- Roche Stop Fuga de Cerebros
- Basque Government
- Eusko Jaurlaritza
Zitieren
APA
Moreno-Martinez, L., Gaja-Capdevila, N., Mosqueira-Martín, L., Herrando-Grabulosa, M., Rodriguez-Gomez, L., Gonzalez-Imaz, K., Calvo, A. C., Sagartzazu-Aizpurua, M., Moreno-García, L., Fuentes, J. M., Acevedo-Arozena, A., Aizpurua, J. M., Miranda, J. I., López de Munain, A., Vallejo-Illarramendi, A., Navarro, X., Osta, R., & Gil-Bea, F. J. (2025). Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1 G93A amyotrophic lateral sclerosis (ALS) mice. British Journal of Pharmacology. https://doi.org/10.1111/bph.17448
Vancouver
Moreno-Martinez L, Gaja-Capdevila N, Mosqueira-Martín L, Herrando-Grabulosa M, Rodriguez-Gomez L, Gonzalez-Imaz K, et al. Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1 G93A amyotrophic lateral sclerosis (ALS) mice. British Journal of Pharmacology. 2025. doi:10.1111/bph.17448
BibTeX
@article{MorenoMartinez2025,
author = {Moreno-Martinez, Laura and Gaja-Capdevila, Núria and Mosqueira-Martín, Laura and Herrando-Grabulosa, Mireia and Rodriguez-Gomez, Laura and Gonzalez-Imaz, Klaudia and Calvo, Ana C and Sagartzazu-Aizpurua, Maialen and Moreno-García, Leticia and Fuentes, Jose Manuel and Acevedo-Arozena, Abraham and Aizpurua, Jesús María and Miranda, José Ignacio and López de Munain, Adolfo and Vallejo-Illarramendi, Ainara and Navarro, Xavier and Osta, Rosario and Gil-Bea, Francisco Javier},
title = {Novel FKBP prolyl isomerase 1A (FKBP12) ligand promotes functional improvement in SOD1 G93A amyotrophic lateral sclerosis (ALS) mice},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17448}
}
EUVIMED